Mark W. Albers is a neurologist specializing in memory and olfactory disorders. He earned a PhD in organic chemistry from Harvard University, working in the laboratory of Stuart Schreiber, and an MD degree from the H.S.T. program of Harvard Medical School and M.I.T. He was an internal medicine resident for two years at Massachusetts General Hospital and then trained in neurology at Mass General, and Brigham and Women’s Hospital, where he was one of the first chief residents for the Partners neurology residency program. He completed a postdoctoral fellowship in the laboratory of Richard Axel while he practiced neurology at the Neurological Institute, Columbia University.

At Mass General he sees patients in the Memory Disorders Clinic and attends on the inpatient neurologic wards. His clinical research is focused on developing sensitive probes of olfactory function as a biomarker for early neurodegenerative disease, including Alzheimer’s and TBI, and COVID. His laboratory research focuses on elucidating the mechanisms of neurodegeneration, identifying novel drug targets that mediate neurodegeneration, and developing therapies to prevent neurodegeneration. He is the overall PI of the NADALS trial, the first basket trial in neurodegenerative disease. This drug repurposing clinical trial will test the FDA-approved drug, baricitinib, in patient populations with either Alzheimer’s disease or ALS. He served as a member of the Translational Neuroscience committee of the American Academy of Neurology, is a faculty member of the Harvard Program in Therapeutic Science, the Laboratory of Systems Pharmacology, the Harvard-MIT Center for Regulatory Science, and the McCance Center for Brain Health. He is the Associate Director of the Massachusetts Center for Alzheimer’s Therapeutic Science.